Re: Best / worst turnaround list
>Left out a few that are too obvious (like VLTS).<
VLTS is on the list!
>OCCX – Isn’t this the rheopheresis company that Cramer pumped?<
Yes, it’s a spin-off from TLCV and the ticker used to be RHEO. In the first iHub survey in 2004 on the best and worst biotech stocks, RHEO was my vote for the worst biotech and I continued to pan it at every opportunity. The rheopheresis procedure for dry AMD is a scam, IMO.
>COR – Someone else can comment on this one. I’ll keep my mouth shut.<
You can find plenty of griping on the COR board on iHub, where Neuroinvest (Dr. Tracy) is trying, with limited success, to keep the cult together. (Considering that this was one of David Miller’s picks, I’m surprised that he has not commented on it. Perhaps I missed it.)
Of the listed stocks, COR is a reasonable pick for best 2007 turnaround play because there is at least a clear-cut path that could make this happen.
>DOVP – I don’t know much about DOVP, and their website is confusing as hell. No idea here if the pain drug is promising or not.<
This was my own pick for best 2007 turnaround play among the listed stocks. Why? Because the valuation is so cheap that someone like WYE might just buy them out at a decent premium.
>NTMD – Don’t know enough about BiDil to have an opinion.>
BiDil is a dog but NTMD still has a decent balance sheet. Perhaps they can make something happen with an in-licensing deal.
On most of the other companies you commented on, I’m inclined to agree with your pessimistic prognosis. The most shareholder-friendly option for many of these companies would be to shut down and distribute the remaining cash. Before you say this never happens, let me remind you that CABG Medical did exactly that. Regards, Dew
Market Data 
Markets 
AI
